The government alleges private and public insurers paid millions after receiving claims tied to widespread cardiovascular tests performed on student athletes at college campuses across the United States
WASHINGTON, DC — Federal prosecutors allege that a cardiovascular testing operation involving Texas cardiologist Jason Finkelstein submitted more than $89 million in false claims for student-athlete testing and collected more than $13.1 million from public and private health benefit programs.
The financial totals place the prosecution among the most substantial school-based healthcare-fraud cases announced during the Justice Department’s 2026 national enforcement campaign, although billed charges, reimbursements received, alleged loss, personal compensation, restitution, and forfeiture remain legally distinct measurements.
According to the federal indictment filed in the Southern District of Florida, insurers sent the alleged payments to bank accounts belonging to Cardiovascular Testing Services PA and Cardiovascular Healthcare Associates PA, two Texas professional associations Finkelstein owns.
Prosecutors say approximately $1.1 million later reached Finkelstein through checks and wire transfers tied to reimbursements received by those associations and an unnamed Florida testing company during an alleged conspiracy from January 2019 through December 2025.
Finkelstein has pleaded not guilty and remains presumed innocent, requiring the government to prove every charged element beyond a reasonable doubt instead of treating enormous billing totals, professional ownership, multistate licensing, or insurer payments as automatic evidence of criminal intent.
The $89 Million Figure Represents Claims Submitted
The indictment describes more than $89 million as the aggregate amount of allegedly false and fraudulent claims submitted through interstate wire communications, not money Finkelstein personally received or funds every named payer actually transferred.
Healthcare providers frequently bill amounts exceeding negotiated reimbursement rates, meaning a submitted-charge total can differ dramatically from allowed amounts, patient responsibility, insurer payments, recoverable loss, legitimate service value, and proceeds legally traceable to a charged offense.
Prosecutors will therefore need claim-level evidence showing which services generated the total, which entities submitted each transaction, what representations accompanied every claim, why those representations were material, and how Finkelstein allegedly participated knowingly in the resulting submission process.
Defense lawyers can challenge the aggregate by separating paid from denied claims, identifying services with legitimate clinical value, examining varying insurer rules, testing statistical extrapolations, and arguing that arithmetic alone cannot convert administrative mistakes into intentional fraud.
More Than $13.1 Million Allegedly Reached Company Accounts
The charging document states that commercial plans, the Federal Employees Health Benefits Program, the Veterans Health Administration, and Medicaid paid more than $13.1 million into accounts held by Cardiovascular Testing Services and Cardiovascular Healthcare Associates during the alleged scheme.
That payment figure represents roughly fifteen cents for every dollar billed, a relationship that may reflect contractual discounts, denials, coverage limitations, network arrangements, claims editing, benefit rules, or other reimbursement mechanics that require expert explanation before jurors assess significance.
Prosecutors may argue that millions in successful reimbursements show the alleged misrepresentations repeatedly influenced payment decisions, while the defense may contend that insurers had relevant information, conducted independent reviews, or would have paid particular services despite disputed fields.
The difference between charges and payments also creates a critical evidentiary map, because each denied claim may reveal insurer skepticism, each successful appeal may expose supporting documentation, and every paid transaction can identify the representations prosecutors consider materially deceptive.
The Forfeiture Demand Uses an Even More Specific Number
The indictment’s forfeiture section identifies approximately $13,146,886 as funds allegedly derived from the charged offenses and states that the government may seek that amount as a forfeiture money judgment if qualifying convictions ultimately occur.
Forfeiture is not identical to restitution, because forfeiture generally focuses upon property constituting or derived from criminal proceeds, while restitution ordinarily addresses compensable losses suffered by identifiable victims under governing statutes and later judicial findings.
The government also reserves the ability to pursue substitute property when directly traceable assets cannot be located, have been transferred, were placed beyond the court’s jurisdiction, substantially declined in value, or became commingled beyond practical division.
Nothing in the forfeiture allegation proves the money is criminally derived, because prosecutors must first secure the necessary conviction and establish the required connection between property and offenses before a court can enter a final forfeiture judgment.
Finkelstein’s Alleged $1.1 Million Is a Separate Financial Measure
Prosecutors allege Finkelstein received approximately $1.1 million through checks and wires issued by two unnamed co-conspirators from reimbursements collected by the Texas associations and the Florida company during the six-year period identified in Count One.
That amount is substantially smaller than both the $89 million submitted and $13.1 million paid, underscoring why reporting should not describe every corporate reimbursement as personal income or assume ownership automatically establishes individual receipt and control.
At trial, bank statements, general ledgers, tax records, payroll files, contracts, invoices, distributions, and communications may help determine whether the transfers represented salary, professional fees, ownership distributions, reimbursements, alleged proceeds, or a mix of categories.
The defense may argue that compensation reflected legitimate medical or administrative work, while prosecutors may connect payment timing, account descriptions, internal messages, claim volumes, and alleged knowledge of billing practices to demonstrate financial motive and participation.
Four Payer Categories Allegedly Funded the Reimbursements
The indictment identifies commercial insurance plans, the Federal Employees Health Benefits Program, the Veterans Health Administration, and Medicaid as health benefit programs allegedly deceived through claims for cardiovascular services that prosecutors characterize as unnecessary, ineligible, or misrepresented.
Named commercial organizations include Aetna, Blue Cross and Blue Shield Texas, Capital District, Cigna, UnitedHealth Group, and the University of Pittsburgh Medical Center Health Plan, although particular coverage arrangements and requirements may have varied significantly.
Federal employee plans, veterans’ healthcare arrangements, state-federal Medicaid programs, employer-sponsored coverage, and private managed-care contracts can apply different enrollment standards, authorization rules, coding instructions, payment formulas, appeal procedures, and definitions of medically necessary testing.
Prosecutors must therefore establish materiality within the governing context for relevant claims, rather than presuming that an alleged misstatement influencing one payer carried identical reimbursement consequences for every other program included in the broader financial totals.
The Operation Allegedly Turned Screening into Diagnostic Billing
Prosecutors allege the Florida company promoted no-cost cardiovascular screening to college athletic programs while claiming the resulting procedures were diagnostic services supported by individualized medical necessity and qualifying clinical information for reimbursement.
The indictment says insurers generally covered electrocardiograms, echocardiograms, and several vascular ultrasound examinations when symptoms, history, examination findings, or other clinical circumstances justified diagnosing or managing possible cardiovascular disease under applicable guidelines.
Those programs generally did not reimburse broad screening conducted without a prior medical-necessity determination, except under limited circumstances, creating an alleged financial incentive to make preventive campus events appear like individualized diagnostic encounters.
The central billing question is therefore not whether cardiovascular screening can benefit athletes, but whether the particular services were necessary, accurately described, properly ordered, meaningfully reviewed, and eligible under the rules governing each submitted claim.
False Diagnoses Allegedly Opened the Payment Door
According to prosecutors, participants assigned false diagnosis codes to information gathered from student questionnaires, making athletes appear to have conditions such as hypertension or elevated blood pressure that could support coverage for diagnostic cardiovascular testing.
The government may use original questionnaires, electronic revision histories, vital signs, medical records, diagnosis tables, coding instructions, employee testimony, and claim submissions to show whether diagnoses were deliberately inserted without legitimate clinical support.
Defense attorneys may argue that symptoms were reasonably inferred, athletes supplied incomplete information, software generated codes, nonphysician employees made independent choices, or disputed diagnoses reflected carelessness and coding confusion rather than a knowing agreement to defraud.
Because diagnosis information can remain within a patient’s medical history long after payment, the allegation also raises consequences extending beyond reimbursement, including later underwriting questions, treatment decisions, record correction efforts, and anxiety for affected athletes and families.
Nearly Every Athlete Allegedly Received the Same Six Tests
The indictment says traveling sonographers conducted almost the same six-test panel on participating student athletes, including an electrocardiogram, an echocardiogram, and vascular ultrasound studies examining several anatomical areas during organized campus testing events.
Prosecutors may portray that uniformity as evidence that testing volume preceded individualized clinical judgment, particularly because Finkelstein allegedly served as the only ordering or referring provider and did not examine athletes before procedures occurred across numerous distant schools.
Standardized protocols are not inherently fraudulent, however, because legitimate screening initiatives often apply consistent procedures to defined populations, leaving medical necessity, claim accuracy, consent, professional qualifications, and billing representations as the decisive factual issues.
Financial evidence can connect the repeated panels with revenue by comparing campus rosters, test combinations, claim amounts, reimbursement rates, denial percentages, appeal outcomes, and distributions among the entities and individuals involved in each event.
Place-of-Service Information Allegedly Concealed Campus Testing
Prosecutors allege claims falsely indicated that athletes underwent cardiovascular testing at Finkelstein’s office in Tarrant County, Texas, even though sonographers actually acquired the images during mobile events conducted at school campuses elsewhere across the country.
Service location can affect reimbursement, network status, credentialing, supervision, jurisdiction, technical-component billing, and payer review, meaning a geographic field may carry consequences substantially greater than an insignificant address error within a national operation.
The government may compare claim forms with school calendars, travel records, equipment logs, image metadata, athlete locations, employment files, and electronic platform data to reconstruct where each professional and technical component actually occurred.
The defense may answer that billing conventions associated professional interpretation with a physician office, software populated addresses automatically, payers understood the mobile workflow, or any inaccurate location was immaterial and attributable to administrative personnel.
Appeals Allegedly Kept Denied Revenue in Play
The indictment alleges that Finkelstein and others prepared or caused false documentation to be submitted when appealing claims denied by insurers, potentially making the appeal process a key source of evidence on knowledge, intent, and disputed payment justifications.
Denied claims can reveal precisely what concerned a payer, while appeal letters, attached records, portal histories, recorded calls, resubmissions, and internal instructions may show how company personnel responded after the initial request for payment failed.
Prosecutors may contend that repeated use of inaccurate documentation demonstrates deliberate persistence after notice, whereas the defense may show legitimate disagreements about coverage, good-faith corrections, ambiguous payer guidance, or appeals handled without Finkelstein’s direction.
Additional companies were allegedly formed to circumvent insurer efforts to prevent improper billing and to conceal one co-conspirator’s involvement, an accusation that financial and corporate records may corroborate or explain through lawful business activity.
Digital Records Could Reconstruct the Money Pipeline
Investigators can align electronic health records, image-access logs, billing software entries, clearinghouse transmissions, insurer adjudication files, bank deposits, and outgoing transfers to create a chronological account connecting campus testing with claims and subsequent payments.
That reconstruction may reveal who entered diagnoses, selected service locations, approved reports, transmitted claims, handled denials, directed appeals, opened related companies, controlled bank accounts, and authorized the approximately $1.1 million allegedly paid to Finkelstein.
Digital timestamps nevertheless require authentication and context, because automated events, shared credentials, migrated systems, preliminary reviews, batch processing, clock settings, and vendor workflows can complicate conclusions drawn from a superficially simple electronic sequence.
Both sides will likely rely on forensic accountants and software experts who can explain how individual transactions moved through clinical and financial systems, without letting colorful aggregate charts replace proof of attribution and intent.
Rapid Medical Approvals Allegedly Supported High-Volume Billing
The government alleges Finkelstein routinely approved cardiovascular results within only seconds of accessing them, despite claims identifying him as a reviewing provider and image collections that prosecutors say required meaningful professional examination before reliable reports could issue.
One October 2024 episode allegedly involved approximately sixty-three images for a student athlete, some containing unconfirmed references to possible right-sided heart enlargement, which Finkelstein allegedly signed as normal about eleven seconds after accessing the collection.
Prosecutors say the athlete died from sudden cardiac arrest approximately twenty-four days later, adding profound human gravity to a case whose headline figures might otherwise appear like an abstract dispute about codes, contracts, and reimbursement calculations.
The death does not prove healthcare fraud, financial loss, causation, or criminal intent, and defense counsel may challenge the annotations, timing, clinical significance, later events, image quality, other professionals’ responsibilities, and the government’s interpretation.
The Case Includes One Conspiracy Count and Three Executions
Count One charges conspiracy to commit healthcare fraud and wire fraud, alleging that Finkelstein knowingly joined others in a plan operating from approximately January 2019 through December 2025 in Florida and elsewhere across the United States.
Counts Two through Four charge substantive healthcare fraud involving two abdominal aorta ultrasound claims billed at approximately $150 each and one broader cardiovascular panel billed at approximately $975 for the athlete identified as K.F.
Those three transactions are tiny beside the aggregate $89 million allegation, making the distinction between the government’s broad scheme narrative and the specific executions selected for substantive charges particularly important during trial and deliberations.
Jurors must evaluate each count separately under Judge Aileen Cannon’s instructions, determining whether evidence proves the required representations, materiality, knowledge, willfulness, causation, and participation beyond a reasonable doubt for every charged federal offense presented during deliberations.
An August 2022 Text Exchange May Illuminate One Service
The indictment describes messages in which an unnamed operations executive asked Finkelstein about an abdominal aorta ultrasound, while he allegedly responded that he did not read those studies and questioned why the operation performed them.
Prosecutors say claims for abdominal aorta ultrasounds nevertheless continued until approximately January 2024, potentially allowing the exchange to support an inference that billed representations and actual review practices diverged after direct internal discussion.
Defense lawyers can seek the complete conversation, surrounding records, terminology, workflow assignments, preliminary-reader information, and witness testimony, arguing that isolated texts can be ambiguous or misleading when removed from their operational and clinical context.
Because two substantive counts involve abdominal aorta ultrasounds, the government may attempt to connect this exchange with transaction-specific proof, while the defense can insist that general skepticism does not establish every element for identified claims.
The Payment Ratio Will Require Careful Expert Explanation
Approximately $13.1 million paid against more than $89 million billed creates a reimbursement ratio near fifteen percent, but that calculation alone cannot reveal which claims were fraudulent, which services possessed value, or why individual payers denied most requested charges.
Forensic accountants may separate gross charges, contractual adjustments, allowed amounts, coinsurance, deductibles, denials, recoupments, refunds, appeals, and net deposits, creating a more accurate financial narrative than the dramatic comparison headline numbers alone provide.
Clinical and coding experts can then connect those financial categories with medical necessity, diagnosis support, provider roles, locations, credentials, report quality, and payer rules, helping jurors determine whether alleged falsehoods actually caused particular payments.
The defense may also examine whether the government credited legitimate portions of bundled services, excluded reversals, accounted for differing coverage policies, and distinguished claims connected with properly qualified workers or meaningful physician review from disputed encounters.
Insurers Can Learn from the Alleged Patterns Before Trial
Health plans can compare school event dates, athlete demographics, identical six-test panels, diagnosis distributions, ordering-provider concentration, service locations, technician identities, review intervals, corporate addresses, denial rates, appeals, and bank destinations to flag claims that need closer review.
Analytical anomalies should initiate proportionate review rather than automatic accusations, because legitimate mobile diagnostics, remote interpretation, standardized screening, multistate practice, and software defaults can produce unusual patterns without demonstrating a knowing federal offense.
Payers should publish clear requirements for screening exclusions, medical-necessity documentation, technical and professional components, mobile-service coding, credential records, remote review, ordering relationships, and appeal submissions before providers deliver services and request reimbursement from covered benefit programs.
Earlier coordination among credentialing, claims, clinical review, data analytics, special investigations, and provider education can prevent substantial questionable payments while preserving fair opportunities for honest organizations to fully explain unusual but legitimate operating models.
Schools Face Financial and Clinical Oversight Questions
Colleges considering outside cardiovascular vendors should verify corporate identities, physician licenses, sonographer qualifications, referral payments, insurance billing, student consent, clinical protocols, data security, result communication, escalation of abnormal findings, and responsibility for urgent follow-up care.
Written agreements should identify whether services are optional screening or individualized diagnosis, which entity bills insurers, what students may owe, who selects codes, where each component occurs, and how schools confirm promised professional qualifications.
Athletic departments should preserve proposals, contracts, credential packets, event rosters, consent forms, equipment records, claims disclosures, communications, quality-control results, incident reports, and referral compensation information so reliable evidence can answer later questions.
The allegation that some athletes were told testing was mandatory for team participation makes transparent financial disclosure especially important, because students facing institutional pressure may not understand that insurers could receive substantial claims after a no-cost campus event.
Athletes and Families Need Complete Billing Transparency
Before testing, athletes should receive understandable notice explaining why each procedure is recommended, whether participation is optional, who performs and interprets the study, what qualifications those professionals hold, and which health plan may receive charges.
They should also know which diagnoses could enter permanent medical records, whether cost sharing may arise, how to obtain original images and reports, where to correct billing disputes, and who communicates dangerous abnormalities requiring immediate action.
A promise that services impose no direct cost does not establish that testing is medically necessary, properly credentialed, meaningfully reviewed, accurately coded, or eligible for reimbursement, particularly when a third-party insurer bears most of the financial consequence.
Clear explanation protects informed choice while enabling athletes, parents, schools, and insurers to identify discrepancies early, before disputed diagnoses, inaccurate locations, questionable reports, or unexpected claims become embedded across multiple interconnected healthcare administrative systems.
Public Reporting Must Keep Every Financial Figure in Its Lane
Associated Press coverage of the national healthcare-fraud crackdown placed Finkelstein’s case within the wider 2026 enforcement action while describing allegations involving unnecessary tests, false diagnoses, multistate licensing, rapid approvals, insurer billing, and the student athlete’s death.
Responsible coverage should say prosecutors allege more than $89 million was submitted and more than $13.1 million was paid, rather than reporting either number as proven theft, established loss, personal profit, or a final restitution obligation.
News organizations should also identify this as a mixed public-and-private insurance prosecution, because casually calling it a Medicare case would misstate the payer list set out in the indictment and distort how the alleged operation generated revenue.
The presumption of innocence belongs near the financial allegations throughout continuing coverage, since large numbers can create an impression of certainty even when evidence remains untested, legal theories disputed, and every count unresolved.
Crisis Communication Must Follow Verifiable Records
Healthcare companies, schools, insurers, and professionals facing comparable allegations need disciplined statements that protect patient privacy, avoid influencing witnesses, separate verified facts from accusations, acknowledge legitimate concerns, and refrain from declaring guilt or exoneration prematurely.
Amicus International Consulting’s crisis public relations guidance emphasizes structured assessment, timely planning, and consistent stakeholder communication, principles that can support responsible responses while legal counsel preserves evidence and manages disclosure obligations during extended litigation.
Its approach to rebuilding a damaged public reputation similarly favors sustained and verifiable communication, although ethical reputation work cannot erase authentic court records, manipulate financial evidence, suppress legitimate reporting, or substitute favorable messaging for accountability after proven misconduct.
Organizations should explain which records they are preserving, how affected patients can request information, whether independent clinical review is available, and what safeguards have changed, without speculating about disputed criminal responsibility before adversarial testing occurs.
The Financial Allegations Remain Scheduled for Jury Testing
The case remains pending before Judge Aileen Cannon in West Palm Beach, where a status conference is scheduled for September 16, 2026, a calendar call for March 30, 2027, and jury trial for April 5, 2027.
Those dates may change through later court orders as extensive discovery, expert analysis, evidentiary motions, witness preparation, negotiations, and logistical questions ultimately shape whether the case reaches trial on the presently published federal schedule.
If trial proceeds, prosecutors will ask jurors to view campus recruitment, uniform testing, false diagnoses, disputed locations, rapid approvals, appeals, corporate structures, bank deposits, and personal transfers as connected components of deliberate financial deception.
Defense attorneys will attempt to separate those components, challenge attribution and materiality, identify legitimate services, question aggregate calculations, offer alternative explanations for payments, and insist that regulatory or clinical shortcomings do not automatically become federal fraud.
The Numbers Describe Scale but Cannot Decide Guilt
The indictment’s central financial story moves from more than $89 million in submitted claims to more than $13.1 million in insurer payments, then narrows further to approximately $1.1 million allegedly received by Finkelstein personally during the charged period.
That sequence helps explain why prosecutors describe a nationwide operation rather than isolated billing mistakes, yet the figures cannot establish who entered each diagnosis, reviewed each image, transmitted each claim, controlled each account, or understood every representation.
For jurors, the challenge will involve moving between sweeping totals and specific evidence, ensuring that the emotional force of a student’s death and the visual power of millions of dollars never displace count-by-count legal analysis.
For healthcare organizations, schools, insurers, athletes, and families, the case offers an immediate compliance warning about what can happen when clinical purpose, professional responsibility, informed consent, claim accuracy, and payment oversight become fragmented across a national network.
Jason Finkelstein remains presumed innocent, and the government’s estimates will remain allegations unless prosecutors prove through reliable evidence that the charged transactions and wider agreement satisfied every required element beyond a reasonable doubt.
